BioLine RX Stock

BioLine RX Debt

The Debt of BioLine RX (BLRX.TA) as of Sep 3, 2026 is 15.04 M USD. In the previous year, Debt was 11.59 M USD — a change of 29.76% (higher).

Debt

15.04 MUSD

YoY

29.76%

Last updated:

In 2026, BioLine RX's total debt was 15.04 M USD, a 29.76% change from the 11.59 M USD total debt recorded in the previous year.

The BioLine RX Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2017
250,000.00 USD
Jan 1, 2018
8.73 M USD
Jan 1, 2019
10.46 M USD
Jan 1, 2020
7.68 M USD
Jan 1, 2021
4.65 M USD
Jan 1, 2022
12.32 M USD
Jan 1, 2023
11.59 M USD
Jan 1, 2024
15.04 M USD
The BioLine RX Debt history
YEARDebtYoY
15.04 MUSD+29.76%
11.59 MUSD-5.95%
12.32 MUSD+164.98%
4.65 MUSD-39.47%
7.68 MUSD-26.50%
10.46 MUSD+19.72%
8.73 MUSD+3,393.20%
250,000.00USD-27.11%
343,000.00USD-21.51%
437,000.00USD—
0.00USD—
Access this data via the Eulerpool API
Get Free API Key

BioLine RX Stock analysis

What does BioLine RX do? BioLine RX Ltd is a global biopharmaceutical company specializing in the development of novel therapies for cancer and other serious diseases. The company is headquartered in Israel and has offices in the United States and Europe. BioLine RX is one of the most popular companies on Eulerpool.

Debt Details

Understanding BioLine RX's Debt Structure

BioLine RX's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing BioLine RX's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to BioLine RX’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in BioLine RX’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about BioLine RX stock

Debt of BioLine RX is 15.04 M USD in 2026.

Debt of BioLine RX changed from 11.59 M USD to 15.04 M USD, representing a 29.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Debt BioLine RX since 2006 – with annual values, charts, and detailed analysis.

Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's BioLine RX historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — BioLine RX

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BioLine RX